

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) hereby announces that Mr. ZHANG Cuilong (“**Mr. ZHANG**”) was appointed as an executive director of the Company with effect from 9 July 2018.

Mr. ZHANG, aged 50, joined a member of the Group in 1996 and is currently a president of the oncology drug business division of the Group. Mr. ZHANG holds a bachelor’s degree in pharmacology from Hebei Medical College (now known as Hebei Medical University) and has more than 25 years of technical, marketing and management experience in the pharmaceutical industry.

Mr. ZHANG has entered into a service contract with the Company for a period of three years commencing from 9 July 2018 and his appointment is subject to retirement and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. ZHANG is entitled to receive a monthly salary of RMB57,750 and an annual director’s fee of HK\$60,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having given consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

Mr. ZHANG does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company, and has not held any directorships in any listed public companies in the last three years. As at the date of this announcement, Mr. ZHANG does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed above, there is no other information to be disclosed pursuant to rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and there is no other matter which needs to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. ZHANG.

The Board warmly welcomes Mr. ZHANG to join the Board.

By order of the board  
**CSPC Pharmaceutical Group Limited**  
CAI Dongchen  
*Chairman*

Hong Kong, 9 July 2018

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei, Mr. ZHANG Cuilong and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*